A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.
Publication
, Journal Article
Laskowitz, DT; Kolls, BJ
Published in: Neurology
June 15, 2010
Duke Scholars
Published In
Neurology
DOI
EISSN
1526-632X
Publication Date
June 15, 2010
Volume
74
Issue
24
Start / End Page
2026
Location
United States
Related Subject Headings
- Neurology & Neurosurgery
- Humans
- Dose-Response Relationship, Drug
- Clinical Trials, Phase II as Topic
- Apolipoprotein E4
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal
- Alzheimer Disease
- 3209 Neurosciences
- 3202 Clinical sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Laskowitz, D. T., & Kolls, B. J. (2010). A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology, 74(24), 2026. https://doi.org/10.1212/WNL.0b013e3181e03844
Laskowitz, Daniel T., and Brad J. Kolls. “A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.” Neurology 74, no. 24 (June 15, 2010): 2026. https://doi.org/10.1212/WNL.0b013e3181e03844.
Laskowitz DT, Kolls BJ. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2010 Jun 15;74(24):2026.
Laskowitz, Daniel T., and Brad J. Kolls. “A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.” Neurology, vol. 74, no. 24, June 2010, p. 2026. Pubmed, doi:10.1212/WNL.0b013e3181e03844.
Laskowitz DT, Kolls BJ. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2010 Jun 15;74(24):2026.
Published In
Neurology
DOI
EISSN
1526-632X
Publication Date
June 15, 2010
Volume
74
Issue
24
Start / End Page
2026
Location
United States
Related Subject Headings
- Neurology & Neurosurgery
- Humans
- Dose-Response Relationship, Drug
- Clinical Trials, Phase II as Topic
- Apolipoprotein E4
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal
- Alzheimer Disease
- 3209 Neurosciences
- 3202 Clinical sciences